Valley Brook Capital Group’s Pfizer PFE Stock Holding History

Valley Brook Capital Group’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,250	Closed	-$296K	–	112
2023 Q1	$296K	Sell	7,250 -3,398	-32%	-$147K	0.27%	85
2022 Q4	$546K	Hold	10,648	–	–	0.52%	57
2022 Q3	$465K	Hold	10,648	–	–	0.51%	54
2022 Q2	$558K	Hold	10,648	–	–	0.58%	50
2022 Q1	$551K	Buy	10,648 +270	+3%	+$14K	0.48%	59
2021 Q4	$612K	Hold	10,378	–	–	0.53%	55
2021 Q3	$446K	Sell	10,378 -500	-5%	-$22.1K	0.44%	61
2021 Q2	$425K	Sell	10,878 -875	-7%	-$34K	0.41%	65
2021 Q1	$425K	Sell	11,753 -350	-3%	-$12.4K	0.38%	59
2020 Q4	$445K	Buy	+12,103	New	+$444K	0.44%	57

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Valley Brook Capital Group's PFE Position: Q2 2023 in Review

Valley Brook Capital Group sold out of Pfizer (PFE) in Q2 2023, closing a stake of 7,250 shares — an estimated $296K sold.

Valley Brook Capital Group first reported a position in PFE in Q4 2020 and held it in 10 quarters. The position peaked at $612K in Q4 2021. 3,042 funds tracked by Wall St. Rank hold PFE as of Q2 2023.

Valley Brook Capital Group reported no remaining Pfizer position as of Q2 2023 after selling out during the quarter.
Valley Brook Capital Group sold 7,250 Pfizer shares in Q2 2023, an estimated $296K.
Valley Brook Capital Group first reported a position in Pfizer in Q4 2020 and held it in 10 quarters.
Valley Brook Capital Group's Pfizer position peaked at $612K in Q4 2021.
3,042 funds tracked by Wall St. Rank held Pfizer as of Q2 2023.

Based on Valley Brook Capital Group's 13F filing for Q2 2023, filed 31 Jul 2023.